Zimmer Biomet (ZBH) – Research Analysts’ Recent Ratings Updates

Zimmer Biomet (NYSE: ZBH) has recently received a number of price target changes and ratings updates:

  • 5/31/2024 – Zimmer Biomet had its price target lowered by analysts at Barclays PLC from $130.00 to $125.00. They now have an “underweight” rating on the stock.
  • 5/30/2024 – Zimmer Biomet is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $129.00 price target on the stock.
  • 5/30/2024 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 5/21/2024 – Zimmer Biomet was upgraded by analysts at Argus from a “hold” rating to a “buy” rating. They now have a $150.00 price target on the stock.
  • 5/17/2024 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 5/3/2024 – Zimmer Biomet had its price target raised by analysts at Oppenheimer Holdings Inc. from $150.00 to $155.00. They now have an “outperform” rating on the stock.
  • 5/3/2024 – Zimmer Biomet had its price target lowered by analysts at Truist Financial Co. from $137.00 to $130.00. They now have a “hold” rating on the stock.
  • 5/2/2024 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Needham & Company LLC.

Zimmer Biomet Trading Down 0.4 %

Shares of ZBH stock opened at $112.88 on Tuesday. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $147.50. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The business’s 50 day moving average is $120.26 and its two-hundred day moving average is $122.06. The company has a market cap of $23.22 billion, a PE ratio of 24.43, a price-to-earnings-growth ratio of 2.04 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBHGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the company posted $1.89 earnings per share. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 annualized dividend and a yield of 0.85%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. Norges Bank bought a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $266,896,000. Price T Rowe Associates Inc. MD boosted its position in shares of Zimmer Biomet by 12.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider’s stock valued at $1,404,638,000 after acquiring an additional 1,215,935 shares during the period. American Century Companies Inc. boosted its position in shares of Zimmer Biomet by 21.2% in the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after acquiring an additional 852,186 shares during the period. Boston Partners boosted its position in shares of Zimmer Biomet by 26.3% in the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider’s stock valued at $437,413,000 after acquiring an additional 691,191 shares during the period. Finally, Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 23.7% in the fourth quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock valued at $345,452,000 after acquiring an additional 543,344 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Read More

Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.